Date of publication: April 09, 2021

Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of COVID-19 Vaccine AstraZeneca. This assessment follows the HTAC evaluation framework to assess COVID-19 vaccines using the following criteria: (1) responsiveness to magnitude and severity; (2) clinical efficacy and safety; (3) affordability and viability; (4) household financial impact; (5) social impact; and (6) responsiveness to equity.

HTAC is actively on the watch for evidence as it is rapidly evolving, and shall update its recommendation when new information becomes available.

Evidence summaryhttp://bit.ly/ES-SinovacC19

 

HTAC Interim Recommendation Preview:

ES_SARS-CoV-2_Vaccine_Vero_cell_Inactivated_CoronaVac_v1.0.docx-pages-4-7